PubMed Health⌕ Search

Biomedical subjects

Jørn Dalsgaard Nielsen

Publications and source records attributed to Jørn Dalsgaard Nielsen.

7 recordsLinked to original sources
PubMed2006

[The antithrombotic-treated patient].

Management of perioperative treatment with anticoagulants and antiplatelet drugs is a complex medical problem. Careful preoperative evaluation of the risk of bleeding and thromboembolism with and without of antithrombotic therapy is the key prerequisite to secure safe outcome of elective, invasive procedures performed on patients treated with antithrombotic agents. In emergency cases, knowledge of the pharmacokinetics and pharmacodynamics of antithrombotic drugs and of the effect of antidotes and blood-derived, recombinant, and other haemostatic products is important.

Anticoagulants↗
PubMed2005

[The use of venous thromboprophylaxis in Danish medical departments. A questionnaire survey].

INTRODUCTION: Our goal was to investigate the use of venous thromboprophylaxis in Danish hospital departments of internal medicine, neurology and intensive care. MATERIALS AND METHODS: All 242 Danish departments/wards received a two-page survey form to complete. Two reminders were sent. RESULTS: Eighty-two percent responded. Ninety percent use thromboprophylaxis, but only 69% of intensive care wards, 36% of neurological wards, and 22% of internal medicine wards have established general guidelines for its use. There is no difference between hospitals in larger cities and those in smaller cities. The most usual indication was prolonged bed rest. DISCUSSION: Compared with the scientific documentation, the use of thromboprophylaxis in Danish medical wards must be considered insufficient.

Anticoagulants↗
PubMed2005

[Increased bleeding tendency induced by beta-lactam antibiotics].

Bleeding induced by beta-lactam antibiotics was reported for the first time in 1970. The phenomenon has been confirmed in subsequent studies but has never resulted in any general recommendations for, e.g., screening and treatment. Over a period of seven months, we diagnosed in our department three cases of presumed beta-lactam-induced bleeding in patients treated with high-dose penicillin for endocarditis and septic shock.

Aged↗
PubMed2003

[Effect of Coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial].

INTRODUCTION: A few case-stories claim that the anti-oxidant Coenzyme Q10 and possibly also Ginkgo biloba interact with warfarin treatment. A decreased response to warfarin in the Coenzyme Q10 cases and an increased response in the Ginkgo biloba case have been described. MATERIAL AND METHODS: Twenty-four outpatients on stable, long-term warfarin treatment were included in a randomised, double blind, placebo-controlled crossover trial. Coenzyme Q10 100 mg daily, Ginkgo-Biloba 100 mg daily and placebo were given in random order over treatment periods of four weeks, each followed by a two week wash out period. The international normalized ratio (INR) INR was kept between 2.0 and 4.0 by appropriate adjustment of the warfarin dosage. RESULTS: Fourteen women and ten men, median ages 64.5 years (33-79) were included. Three patients withdrew from the study for personal reasons. The INR was stable during all treatment periods. The geometric mean dosage of warfarin did not change during the treatment periods: Ginkgo biloba 36.7 mg/week (95% confidence interval: 29.2-46.0); CoQ10 36.5 mg/week (29.1-45.8); placebo 36.0 mg/week (28.6-45.1). CONCLUSION: The study indicated that Coenzyme Q10 and Ginkgo biloba do not influence the clinical effect of warfarin.

Adult↗